Arcus Biosciences Inc Dossier - Source-backed chat

Arcus Biosciences Inc

RCUSNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.87

Intrinsic Value $20.86median of 2 methodsbased on filings through 30 Jun 2026

Market Price $25.83Price as of 30 Sep 2026

OvervaluedIntrinsic value is 19% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $3.2B

Enterprise Value $3.2B

Shares Outstanding 130.8M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Arcus Biosciences is undergoing a strategic pivot, shifting its primary focus to its high-potential HIF-2a inhibitor, casdatifan, following the discontinuation of its Phase 3 TIGIT program (STAR-121) in April 2026. Casdatifan has demonstrated a potentially best-in-class clinical profile in clear cell renal cell carcinoma (ccRCC), showing a 45% confirmed ORR and a median PFS of 15.1 months in late-line monotherapy, which significantly outperforms the current standard-of-care belzutifan. Backed by a robust cash position of $876 million (providing runway into the second half of 2028) and a strategic partnership with Gilead, Arcus is well-positioned to aggressively advance casdatifan into Phase 3 trials in both second-line (PEAK-1) and first-line settings by the end of 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets12 analysts · as of 18 Aug 2026

Low · most bearish analyst$23.00

Mean target$38.33

High · most bullish analyst$47.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$23.0020%

The Phase 3 PEAK-1 trial experiences enrollment delays or fails to replicate the strong Phase 1/1b efficacy results. Competitor therapies or next-generation HIF-2a inhibitors show superior profiles, eroding casdatifan's market potential. The transition of the Gilead partnership leads to reduced funding support, accelerating cash burn and shortening the runway, forcing dilutive equity raises before pivotal readouts.

Base CaseCentral scenario

$38.3350%

Matches the consensus mean

Arcus successfully completes enrollment for the Phase 3 PEAK-1 trial by year-end 2026 and initiates its first-line Phase 3 ccRCC trial. Casdatifan continues to show superior efficacy metrics compared to belzutifan in ongoing data readouts. The cash burn decreases as expected due to the wind-down of the domvanalimab trials, leaving the company with approximately $600 million in cash at the end of 2026 and maintaining a runway into 2H 2028. Gilead continues to support the remaining optioned assets.

Bull CaseUpside scenario

$47.0030%

Casdatifan successfully establishes itself as the premier first-line and second-line therapy in ccRCC, capturing over 50% of the market share. The Phase 3 PEAK-1 trial meets its endpoints with superior efficacy over cabozantinib monotherapy, and the first-line TKI-free combination trial initiates smoothly. Additionally, the emerging inflammation and immunology (I&I) portfolio, led by the MRGPRX2 antagonist AB102, delivers positive early clinical data, unlocking a multi-billion dollar non-oncology market opportunity.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Casdatifan has demonstrated a highly differentiated, potentially best-in-class clinical profile in ccRCC, with a median PFS (15.1 months) nearly triple that of the approved competitor belzutifan (5.6 months).
Strong balance sheet with $876 million in cash and investments as of Q1 2026, providing a secure operational runway until at least the second half of 2028.
Strategic collaborations with industry giants Gilead Sciences and AstraZeneca provide clinical infrastructure, co-development support, and validation.
Rapidly emerging, wholly owned inflammation and immunology (I&I) portfolio (e.g., AB102 entering the clinic in Q3 2026) provides significant long-term strategic optionality.

Key Investment Risks

High concentration of clinical value in a single lead asset (casdatifan) following the discontinuation of the late-stage TIGIT program (domvanalimab).
Clinical and regulatory risks inherent to late-stage oncology trials, including potential safety signals or failure to meet primary endpoints in PEAK-1.
Strategic uncertainty surrounding the Gilead collaboration as broad option rights expire on July 14, 2026.
Intense competition in the renal cell carcinoma space from established players like Merck (belzutifan) and Bristol Myers Squibb.

Thesis Invalidation Triggers

Failure of the Phase 3 PEAK-1 trial to meet its primary progression-free survival (PFS) or overall survival (OS) endpoints.
Inability to initiate the Phase 3 first-line ccRCC trial for casdatifan by the end of 2026.
A safety signal or high rate of adverse events emerging in the casdatifan combination cohorts.
Gilead completely exiting the collaboration or declining to exercise options on remaining pipeline assets.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.